LUCEDEX: A prospective study comparing ranibizumab plus dexamethasone combination therapy versus ranibizumab monotherapy for neovascular age-related macular degeneration

Retina

Volumn 33, Issue 8, 2013, Pages 1600-1604

  Ranchod, Tushar M ^a   Ray, Subhransu K ^a   Daniels, Stewart A ^a   Leong, Craig J ^a   Ting, T Daniel ^a   Verne, Allen Z ^a  

^a Bay Area Retina Associates   (United States)

Author keywords

dexamethasone; neovascular age related macular degeneration; ranibizumab

Indexed keywords

DEXAMETHASONE; RANIBIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; EYE; FEMALE; HUMAN; MALE; MEMBRANE; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; TREATMENT INDICATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MALE; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84883743993     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318285cb71     Document Type: Article

References (17)

1. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-572.
2. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131:541-560.
3. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
4. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
5. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization. Retina 2005;25:685-690.
6. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
7. Lip PL, Blann AD, Hope-Ross M, et al. Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. Ophthalmology 2001;108:705-710.
8. Thompson JT. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol 2006;141:629-637.
9. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of bloodretinal and blood-aqueous barrier breakdown. Exp Eye Res 2005;80:249-258.
10. Tamura H, Miyamoto K, Kiryu J, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005; 46:1440-1444.
11. Wenzel A, Grimm C, Seeliger MW, et al. Prevention of photoreceptor apoptosis by activation of the glucocorticoid receptor. Invest Ophthalmol Vis Sci 2001;42:1653-1659.
12. Meikle AW, Tyler FH. Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med 1977;63:200-207.
13. Blankenship GW. Evaluation of a single intravitreal injection of dexamethasone phosphate in vitrectomy surgery for diabetic retinopathy complications. Graefes Arch Clin Exp Ophthalmol 1991;229:62-65.
14. Shah GK, Stein JD, Sharma S, et al. Visual outcomes following the use of intravitreal steroids in the treatment of postoperative endophthalmitis. Ophthalmology 2000;107: 486-489.
15. Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 2012;32:434-457.
16. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, shamcontrolled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-1146 e3.
17. Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118:2453-2460.